Over the past decade, cancer treatment has undergone a significant transformation, with antibody-based immunotherapies targeting immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and its ligand (PD-L1), emerging as a significant therapeutic approach for many breast cancer patients [7,25]. This evidence concerns the gene PDCD1 and breast carcinoma.